

Ref: FOI/CAD/ID 3443

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone  
Kent  
ME16 9QQ

Email: mtw-tr.foiadmin@nhs.net

15 September 2016

### **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to carcinoma and melanoma.

*Please can you supply the following information?*

*1. The number of patients with NON SMALL CELL LUNG CARCINOMA (Stage IIIB/Stage IV) treated in the last 6 months with the following:*

*Afatinib (Giotrif)*

*Ceritinib (Zykadia)*

*Crizotinib (Xalkori)*

*Erlotinib (Tarceva)*

*Gefitinib (Iressa)*

*Pemetrexed (Alimta)*

*Nivolumab (Opdivo)*

*Nintedanib (Vargatef)*

*2. The number of patients with METASTATIC MELANOMA Stage IV (advanced or metastatic), treated in the last 6 months with the following:*

*Ipilimumab (Yervoy)*

*Nivolumab (Opdivo)*

*Ipilimumab AND Nivolumab*

*Pembrolizumab (Keytruda)*

*Vemurafenib (Zelboraf)*

*Vemurafenib AND Cobimetinib*

*Dabrafenib (Taflinar)*

*Trametinib (Mekinist)*

*Dabrafenib AND trametinib*

*Dacarbazine (DTIC)*

For the period 1/1/2016-30/06/2016

1. 20

2. 15